Coronary Calcium & Cholesterol Learning Path

A CAC scan is a non-contrast CT image of the heart that detects calcified plaque in the walls of the coronary arteries. Calcium is a marker that atherosclerotic plaque is present; it does not show how narrow an artery is and does not detect non-calcified plaque.

Results are commonly reported as an Agatston score, sometimes with a percentile that compares the score with people of similar age, sex, and background.

Commonly used educational categories: 0 (no detectable calcium), 1–99 (mild), 100–299 (moderate), and 300 or higher (more extensive). Some reports and guidelines use slightly different cut points, so your report's own wording and your clinician's explanation take priority.

At a population level, scores in this range indicate that calcified plaque is clearly present and are associated with a higher average risk of future cardiovascular events than a score of 0. Many professional guidelines treat this range as a reason to discuss risk-factor management more actively.

A population statistic is not a prediction for any one person. Age, percentile, the number of arteries involved, other risk factors, and symptoms all shape how a clinician interprets an individual result.

Atherosclerotic cardiovascular disease (ASCVD) risk is shaped by many factors together: LDL-C, non-HDL-C, ApoB, Lp(a), triglycerides, blood pressure, diabetes or glycemic status, smoking, kidney function, physical activity, diet, sleep, weight, family history, and any prior heart attack, stroke, or revascularization.

CAC is one piece of that picture. It is typically discussed alongside these risk factors, not instead of them. New symptoms such as chest discomfort or breathlessness need prompt clinical assessment regardless of any prior score.

Statins reduce the liver's production of cholesterol by inhibiting HMG-CoA reductase, which increases LDL receptors on liver cells and lowers circulating LDL-C.

In broad educational terms, guideline literature describes high-intensity regimens as lowering LDL-C by roughly 50% or more on average, moderate-intensity by roughly 30–49%, and low-intensity by less than 30%. Individual responses vary.

Commonly discussed safety and monitoring topics include muscle symptoms, liver tests, a small increase in the chance of a diabetes diagnosis in some people, drug interactions, and follow-up lipid testing.

PCSK9 is a protein that causes LDL receptors to be broken down. Less PCSK9 activity means more LDL receptors and lower LDL-C.

Injectable monoclonal antibodies (evolocumab and alirocumab) bind PCSK9 and are approved in many jurisdictions. Published trials report substantial additional LDL-C lowering when added to statins.

Inclisiran is a small interfering RNA (siRNA) that reduces the liver's production of PCSK9 and is given by injection at long intervals where it is authorized.

Approval, reimbursement, and eligibility criteria differ by country and change over time. Whether any of these is appropriate is a decision for a locally licensed clinician.